Kura Oncology KURA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$73.33M+9.5% | -$81M-9.3% | -$74.12M-12.1% | -$66.12M-15.1% | -$57.43M-199% | ||
| $355K-11.9% | $403K+146% | $164K-26.8% | $224K-7.1% | $241K+18.1% | ||
| $8.42M-25.9% | $11.35M+3.5% | $10.97M+57.8% | $6.95M-11.4% | $7.84M-9.1% | ||
| $106K+2.9% | $103K-27.0% | $141K+2.2% | $138K+3.8% | $133K-5.0% | ||
| $544K— | —— | —— | —— | $46.69M+8,965% | ||
| $430K+316% | $103.25K0.0% | $103.25K0.0% | $103.25K0.0% | $103.25K— | ||
| $2.03M— | —— | $12.72M— | —— | $3.14M+176% | ||
| -$16.22M— | —— | —— | —— | -$8.61M-305% | ||
| $562K— | —— | $10.29M+37.0% | $7.51M+623% | $1.04M-86.1% | ||
| $204K+72.9% | $118K-60.3% | $297K-19.5% | $369K+42.5% | $259K+10.2% | ||
| -$9.44M-106% | $156.29M+898% | $15.66M— | $0-100% | $34.59M-50.3% | ||
| $3.78M— | —— | —— | —— | $46K— | ||
| -$85.85M— | —— | -$80.63M-180% | -$28.78M+60.0% | -$71.93M-127% | ||
| $128K-94.5% | $2.32M-9.6% | $2.57M+76.1% | $1.46M+399% | $292K-21.5% | ||
| $171.6M-28.4% | $239.78M+73.1% | $138.5M+20.9% | $114.6M-57.4% | $268.71M+11.7% | ||
| $147.5M-16.9% | $177.5M-24.5% | $235.03M+34.3% | $175M+4.4% | $167.6M+14.8% | ||
| -$24.23M+62.5% | -$64.6M-169% | $93.97M— | —— | -$101.41M-6.8% | ||
| $69K-93.9% | $1.14M— | $0-100% | $515K+260% | $143K-82.3% | ||
| —— | —— | —— | —— | —— | ||
| $69K-93.9% | $1.14M— | $0-100% | $515K+260% | $143K-82.3% | ||
| -$110.02M— | —— | —— | —— | -$173.19M-199% | ||
| $900K-34.9% | $1.38M-28.2% | $1.92M-23.7% | $2.52M-5.3% | $2.66M-7.7% | ||
| $106K+2.9% | $103K-27.0% | $141K+2.2% | $138K+3.8% | $133K-5.0% | ||
| $355K-11.9% | $403K+146% | $164K-26.8% | $224K-7.1% | $241K+18.1% | ||
| -$16.22M— | —— | —— | —— | -$8.61M-305% | ||
| $3.78M— | —— | —— | —— | $46K— | ||
| -$689K-223% | $558K-80.6% | $2.88M+147% | $1.17M-33.3% | $1.75M+356% | ||
| $204K+72.9% | $118K-60.3% | $297K-19.5% | $369K+42.5% | $259K+10.2% | ||
| $562K— | —— | $10.29M+37.0% | $7.51M+623% | $1.04M-86.1% | ||
| $171.6M-28.4% | $239.78M+73.1% | $138.5M+20.9% | $114.6M-57.4% | $268.71M+11.7% | ||
| $147.5M-16.9% | $177.5M-24.5% | $235.03M+34.3% | $175M+4.4% | $167.6M+14.8% | ||
| $69K-93.9% | $1.14M— | $0-100% | $515K+260% | $143K-82.3% | ||
| -$9.44M-106% | $156.29M+898% | $15.66M— | $0-100% | $34.59M-50.3% | ||
| $3.78M— | —— | —— | —— | $46K— | ||
| -$85.98M— | —— | -$83.19M-175% | -$30.24M+58.1% | -$72.22M-127% | ||
| -$85.98M— | —— | -$83.19M-175% | -$30.24M+58.1% | -$72.22M-127% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kura Oncology generate?
- Kura Oncology (KURA) generated -$267.2M in operating cash flow over the trailing twelve months.
- What is Kura Oncology's free cash flow?
- After $6.5M of capital expenditures, Kura Oncology's free cash flow was -$271.6M over the trailing twelve months, down 302.9% year over year.
- Where does Kura Oncology's cash flow data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
